In-licensing has historically played an important role at Soligenix. The rights to oral Beclomethasone 17,21-dipropionate (BDP), RiVax™, and ThermoVax® were in-licensed into Soligenix since 2002. In December 2012, we in-licensed SGX94, an innate defense regular (IDR), which regulates the innate immune system to reduce inflammation, eliminate infection and enhance tissue healing. Our strategy is to continue to build and diversify our pipeline of products in our core competencies.

We continue to seek new technologies/opportunities in the in the areas listed below. We will look at opportunities in the clinical stages of development with an emphasis on orphan diseases and areas of high unmet medical need. We would seek a minimum of US commercial rights with regard to any particular opportunity.

Examples of indications of interest are listed below:

HSC Transplant

  • GVHD
  • Conditioning regimens

Supportive Cancer Care

  • Mucositis
  • Cachexia

Gastrointestinal

  • Inflammatory conditions of the GI tract

Biodefense and Infectious diseases

  • Vaccines against bioterror threats
  • Therapeutics for treatment of biological and radiological exposure
  • Ant-infectives

Please direct inquiries to:

Karen Krumeich
Chief Financial Officer
Soligenix, Inc.
29 Emmons Drive – Suite C-10
Princeton, NJ 08540
Phone: (609) 538-8200
Fax: (609) 452-6467
E-mail: kkrumeich@nullsoligenix.com